Clearside Biomedical announced positive results from the Extension Study of its OASIS Phase 1/2a clinical trial of CLS-AX administered by suprachoroidal injection via Clearside’s SCS Microinjector(R) in neovascular age-related macular degeneration participants. These results include the final six-month data from all participants in the Extension Study and augment the previously reported 3-month results and interim extension data. George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer, commented, "We made tremendous progress in 2022 with the commercialization of our first suprachoroidal product by Bausch + Lomb and the positive safety and durability results from our Phase 1/2a OASIS trial. As we advance our CLS-AX wet AMD program with the initiation of our ODYSSEY Phase 2b trial, we continue to build on this significant momentum and will further increase awareness of the broad potential in delivering therapies to the back of the eye using our proprietary SCS platform technology."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLSD:
- 3 Stocks to Buy Today, 2/3/2023, According to Top Analysts
- Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
- 2 “Strong Buy” Penny Stocks That Could Go Boom
- Cantor Fitzgerald pharma/biotech analysts hold a dinner
- Cantor Fitzgerald pharma/biotech analyst hold a luncheon